+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Immunotherapy for Solid Tumors, An Issue of Surgical Oncology Clinics of North America. The Clinics: Surgery Volume 35-2

  • Book

  • March 2026
  • Region: North America
  • Elsevier Health Science
  • ID: 6252468
In this issue of Surgical Oncology Clinics, guest editor Dr. Jashodeep Datta brings his considerable expertise to the topic of Immunotherapy for Solid Tumors. Immunotherapy for solid tumors represents a transformative approach in the field of oncology, and has potential to offer durable responses and long-term remission, even in cancers that have been resistant to conventional therapies. This issue provides a contemporary appraisal of advances in immunotherapy technologies and applications for solid tumors, particularly as they related to the surgical management of these diseases.- Contains 14 relevant, practice-oriented topics including the innovative use of circulating tumor DNA as a biomarker to decipher immunotherapy responses; TCR-engineered T cell therapies for solid tumors; new innovations in CAR-T cell approaches; combining systemic and local/regional approaches to improve immunotherapy sensitivity; mRNA vaccines for cancer treatment; management of immunotherapy toxicities; and more- Provides in-depth clinical reviews on immunotherapy for solid tumors, offering actionable insights for clinical practice- Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create clinically significant, topic-based reviews

Please Note: This is an On Demand product, delivery may take up to 11 working days after payment has been received.

Table of Contents

T-Cell Receptor Engineered T-Cell Therapy: A Rapidly Evolving Treatment Paradigm for Solid Tumors
CAR T-Cell Therapy for Solid Tumors: Clinical Challenges and Current Advancements
Response-Based Immunotherapy in Melanoma: A New Paradigm
Combining Systemic and Local/Regional Approaches to Improve Immunotherapy Sensitivity
Disrupting the Immunosuppressive Myeloid Compartment in Solid Tumors
Dendritic Cell-Based Immunotherapy for Solid Tumors
Leveraging the Human Microbiome to Improve Immunotherapy Sensitivity
mRNA Vaccines for Cancer Treatment
Biomarkers of Immunotherapy Response in Surgical Oncology
Identifying Subsets of Patients with Non-immunogenic Gastrointestinal Cancers for Checkpoint Immunotherapy
B-cell-directed Immunotherapy for Solid Tumors
Oncolytic Virotherapy for Solid Tumors: Clinical Advances and Future Directions
Utility of Circulating Tumor DNA-Based Liquid Biopsies in Patients with Cancer Receiving Immunotherapy
Contemporary Management of Immune Checkpoint Inhibitor-related Adverse Events

Authors

Jashodeep Datta Associate Professor of Surgery | University of Miami Miller School of Medicine, DiMare Family Endowed Chair in Immunotherapy, Assistant Director, Transdisciplinary Research, Co-Leader, Gastrointestinal Site Disease Group, Sylvester Comprehensive Cancer Center, Associate Director, Translational Research | Sylvester Pancreatic Cancer Research Institute, Division of Surgical Oncology, Department of Surgery, University of Miami Medical School, Miami, Florida, USA.